Please login to the form below

Not currently logged in
Email:
Password:

RIPK1 inhibitor

This page shows the latest RIPK1 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Lilly signs $960m deal with Rigel to develop RIPK1 inhibitors

Lilly signs $960m deal with Rigel to develop RIPK1 inhibitors

Rigel already has ongoing pre-clinical activities with its lead CNS penetrant RIPK1 inhibitor candidates. ... The ethos behind RIPK1 inhibitor development is to offer a new kind of approach towards treating a range of autoimmune, inflammatory and

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Latest intelligence

What does HCP engagement look like in a post-Covid world?
HCP engagement has changed as a result of the Covid-19 pandemic, with pharmaceutical companies and agencies having to rapidly adjust to a new way of communicating. Digital channels have become...
Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...